Premium
Role of allogeneic stem cell transplantation in mantle cell lymphoma
Author(s) -
Cohen Jonathon B.,
Burns Linda J.,
Bachanova Veronika
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12442
Subject(s) - mantle cell lymphoma , ibrutinib , medicine , bortezomib , rituximab , lenalidomide , oncology , salvage therapy , transplantation , context (archaeology) , lymphoma , multiple myeloma , leukemia , chemotherapy , chronic lymphocytic leukemia , paleontology , biology
Despite a wide spectrum of treatment options, mantle cell lymphoma ( MCL ) remains a challenging hematologic malignancy to manage. Advances in front‐line therapy, including the monoclonal antibody rituximab and increasing use of cytarabine, have improved remission rates. Autologous hematopoietic cell transplantation ( HCT ) can effectively consolidate remission of MCL , leading to encouraging survival beyond 5 yr. However, nearly all patients with MCL will relapse and require salvage therapy. Novel agents such as ibrutinib, bortezomib, and lenalidomide have dramatically expanded the options for treating relapsed MCL . In this review, we summarize the clinical evidence supporting the use of allogeneic donor HCT in MCL and make recommendations on indications for its use. Data suggest that allogeneic donor HCT is the only curative therapy for patients with poor prognosis or aggressive MCL . Patient selection, timing, and optimal use remain a matter of scientific debate and given the rapidly changing therapeutic landscape of MCL , the outcomes of allogeneic HCT should be interpreted in the context of novel therapeutics.